Research Progress on the Combination of PARP Inhibitors (PARPi) and Immune Checkpoint Inhibitors (ICIs)

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• DNA damage repair (DDR) deficiencies, like poly (ADP-ribose) polymerase (PARP) deficiency, drive cancer development and create therapeutic vulnerabilities.
• PARP inhibitors (PARPi) are effective against homologous recombination (HR) deficient tumors, such as those with BRCA1/2 mutations.

Purpose of the Study:

• To review the mechanisms of PARPi in modulating anti-tumor immune responses.
• To explore the synergistic potential of combining PARPi with immune checkpoint inhibitors (ICIs).
• To summarize clinical studies evaluating the efficacy of PARPi and ICI combination therapy.

Main Methods:

• Review of preclinical and clinical studies on PARPi and ICI combination therapy.
• Analysis of the impact of PARPi on tumor neoantigen expression, interferon (IFN) levels, and PD-1/PD-L1 expression.
• Examination of the role of PARPi in regulating the tumor microenvironment (TME).

Main Results:

• PARPi increase tumor neoantigens, IFN, and PD-1/PD-L1 expression, thereby enhancing anti-tumor immunotherapy.
• The combination of PARPi and ICIs demonstrates potential as an alternative treatment for patients unresponsive to ICI monotherapy.
• PARPi modulate the TME to promote a more robust anti-tumor immune response.

Conclusions:

• Combining PARPi with ICIs represents a rational therapeutic strategy by leveraging PARPi's immune-modulating effects.
• This combination therapy holds promise for improving outcomes in various malignancies, particularly in patients who have not benefited from ICI monotherapy.
• Further clinical investigation is warranted to fully establish the role of PARPi and ICI combinations in cancer treatment.